Hematology Frontier

The 2025 Annual Meeting of the American Society of Hematology (ASH 2025) recently concluded successfully in Orlando, USA. As the “year-end flagship event” in hematology, ASH 2025 presented a series of landmark advances in the field of lymphoma, offering new directions for optimizing clinical practice.

Chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) is a clonal proliferative disorder of mature B cells that predominantly affects older adults and is characterized by a distinctive immunophenotype. At the Late-Breaking Abstract (LBA) session of the 2025 American Society of Hematology (ASH) Annual Meeting, Professor Wojciech Jurczak from the Maria Skłodowska-Curie National Research Institute of Oncology presented the first results of the BRUIN CLL-313 study. This randomized phase III trial compared the efficacy and safety of the non-covalent BTK inhibitor pirtobrutinib with bendamustine plus rituximab (BR) in treatment-naïve patients with CLL/SLL. On-site, Oncology Frontier – Hematology Frontier invited Professor Jurczak to provide insights into the study background, design, and clinical implications, offering forward-looking guidance for clinical practice.

The 2025 Annual Meeting of the American Society of Hematology (ASH) was held from December 6–9 in Orlando, USA, drawing global attention as one of the most influential international conferences…

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative treatment for transfusion-dependent thalassemia (TDT). However, transplant outcomes are influenced by donor type, transplant-related complications, and patient-specific factors, leaving room…

From December 6 to 10, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, USA. The meeting highlighted the latest advances in both clinical hematology and basic research, driving progress in the diagnosis and treatment of hematologic diseases as well as translational research.In this issue, we feature the research achievements of Professor Wang Hui’s team, covering cutting-edge technologies such as 16-color full-spectrum flow cytometry, a weighted cytokine scoring system, and other innovative approaches. These studies provide solid scientific evidence for early precise diagnosis, treatment response assessment, and timely clinical intervention, demonstrating the critical role of technological innovation in modern hematology. We warmly invite readers to engage in further discussion and exchange.

The 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, USA, from December 6 to 9, 2025, bringing together the latest research advances and clinical progress in hematology worldwide. At this year’s meeting, Professor Wang Huafeng’s team from The First Affiliated Hospital, Zhejiang University School of Medicine had six studies accepted, including one oral presentation and five poster presentations, with one poster receiving the ASH Outstanding Abstract Award. These achievements highlight the growing international academic influence of Chinese researchers in the field of acute leukemia.

To promote innovation in the fields of cell therapy and immunotherapy in China, facilitate in-depth discussion of key scientific challenges, and share the latest clinical research advances from a global perspective, the 2025 International Conference on Cell and Immunotherapy (CTI 2025) was held in Hangzhou, China, from November 13–16, 2025. The meeting was jointly organized by Zhejiang University, the International Academy for Clinical Hematology (IACH), the Zhejiang Immunology Society, and the Zhejiang Anti-Cancer Association, and co-hosted by The First Affiliated Hospital, Zhejiang University School of Medicine and Liangzhu Laboratory.

Relapsed/refractory multiple myeloma (RRMM) remains a major clinical challenge due to treatment resistance and poor prognosis, underscoring the urgent need for novel drugs and innovative therapeutic strategies. At the 2025 Annual Meeting of the American Society of Hematology (ASH), Professor Chen Wenming and his team from Beijing Chaoyang Hospital, Capital Medical University presented multiple innovative studies involving bispecific antibodies, the novel agent Eprenetapopt-like TRAIL agonist (Epnamin), and the application of mass spectrometry in minimal residual disease (MRD) monitoring.

The 2025 Annual Meeting of the American Society of Hematology (ASH 2025) has recently concluded successfully in Orlando, USA. As the “grand finale” of the hematology field each year, this meeting showcased a series of cutting-edge breakthroughs in lymphoma research, providing new directions for optimizing clinical practice.

From December 6–9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, USA. As the world’s largest and most influential international conference in hematology, ASH attracts tens of thousands of experts and scholars each year to share the latest advances and breakthrough research in the field.